In the Margins
Hedge-fund billionaire John Paulson has joined the Valeant Pharmaceuticals International board of directors. Paulson has been one of the largest shareholders in the company for several years, but a series of scandals at Valeant over its accounting practices and drug pricing have battered the company’s stock and caused the value of Paulson’s stake to plunge 81% to $245 million at the end of last year from $1.3 billion in 2015. Read the original story from The Wall Street Journal.
Most Read
Guinness Atkinson Funds made history last year when it completed the industry’s first conversions from open-end mutual fund to exchange-traded fund. Since then, a number of ...
In late 2020, the Securities Exchange adopted new rule 18f-4 under the Investment Company Act of 1940, which provides for an updated and comprehensive regulatory approach ...
In a speech on Monday, William Birdthistle, the new director of the Securities and Exchange Commission's Division of Investment Management, pondered whether mutual funds are honoring ...
The independent directors of Vanguard Funds were named last week as defendants in a class-action lawsuit brought by a group of retail investors. The plaintiffs' claims ...